Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Regimens in Advanced Colon Cancer
NCT06246461Completed
- Sponsor
- Jingjiang People's Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of capecitabine in colon cancer (3 arms), sponsored by Jingjiang People's Hospital. Primary endpoints: Overall Response Rate at 12 weeks, Disease Control Rate at 12 weeks and 2 more. Started Jan 2022; status: completed.
02
Drugs
capecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06246461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246461.